CD15, CD30, and PAX5 evaluation in Hodgkin's lymphoma on fine‐needle aspiration cytology samples

Cozzolino, Immacolata; Vitagliano, Giulio; Caputo, Alessandro; Montella, Marco; Franco, Renato; Ciancia, Giuseppe; Selleri, Carmine; Zeppa, Pio

doi:10.1002/dc.24366

Cited by 22 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytopathological expression of CD15 occurs in 66,7% of cases. In addition, CD15 resulted to be more effective on smears and cell blocks [84]. CD15 can also be detected as being stained using autoclave and microwave.…”

Section: Experimental Medicine Involving Cd15mentioning

confidence: 98%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

CD15 (Lewis X/Lex) is a fucosyl (3-fucosly-N-acetyl-lactosamine) moiety found on membrane proteins of various cancer cells. These include renal cancer, prostate and bladder cancers, acute leukemias, hepatocellular carcinoma, breast cancer and melanoma. The antigen plays an espe-cially significant role in renal cell carcinoma. Its high expression serves as a good prognostic marker for patients and high hopes are related to its use in the immunotherapy of the tumor. The biological role of CD15 is the interaction with E-, L- and P-selectins (adhesion molecules) and al-lowing for the adhesion with the endothelial cells. In this way, cancer cells start to interact with the endothelium of blood vessels and consequently move out from the blood flow to the sur-rounding tissues. The blockage of antigen’s function results in reduced metastatic potential. Moreover, the molecule may be a therapeutic target against cancer in monoclonal antibod-ies-based therapies. CD15s is a sialyl derivative of CD15, that possess its own unique characteris-tics. Unlike high expression of CD15, which is a prognostic factor in Hodgkin lymphoma, CD15s relate to poor prognosis for the patients. Due to the high abundance in cancer cells, CD15 is con-sidered as a marker of Cancer Stem Cells. This review presents a comprehensive description of the role of CD15 and CD15s in cancer development and metastasis and overviews the clinical appli-cations of the anti-CD15 therapy.

show abstract

Section: Experimental Medicine Involving Cd15mentioning

confidence: 98%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The biological material will then be available for molecular tests. Similarly, the only smear suitable for molecular tests may be stained with immunocytochemistry (most often with hematoxylin and diaminobenzidine) [79][80][81]. Among all the cases included in the present review, only one diaminobenzidine-stained slide was tested as input for the Idylla EGFR system, and it resulted in a false negative result [66].…”

Section: Performance On Different Cytological Samplesmentioning

confidence: 99%

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review

Caputo

D'Ardia

Sabbatino

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

The current standard of care for advanced non-small-cell lung cancer is based on detecting actionable mutations that can benefit from targeted therapy. Comprehensive genetic tests can have long turn-around times, and because EGFR mutations are the most prevalent actionable mutation, a quick detection would enable a prompt initiation of targeted therapy. Furthermore, the scarcity of diagnostic material means that sometimes only cytologic material is available. The Idylla™ EGFR assay is a real-time PCR–based method able to detect 51 EGFR mutations in 2.5 h. Idylla is validated for use only on FFPE sections, but some researchers described their experiences with cytological material. We reviewed the relevant literature, finding four articles describing 471 cases and many types of cytological input material: smears, cell-block sections, suspensions, and extracted DNA. The sensitivity, specificity, and limit of detection appear comparable to those obtained with histological input material, with one exception: the usage of scraped stained smears as input may reduce the accuracy of the test. In conclusion, usage of cytological material as input to the Idylla EGFR test is possible. A workflow where common mutations are tested first and fast, leaving rarer mutations for subsequent comprehensive profiling, seems the most effective approach.

show abstract

“…In addition, a previous work described that PAX5 could be a useful marker in the diagnosis of HL with atypical immunophenotypic characteristics, although in cHL, PAX5 expression may be weaker [ 24 ]. In contrast, several studies have reported that the expression of PAX5 ranges from 88–100% in patients with cHL [ 25 , 26 , 27 , 28 ]. However, the reason for this large range of PAX5 expression could not be clarified.…”

Section: Discussionmentioning

confidence: 99%

“…For this purpose, double immunodetection was performed, finding that there was no nuclear colocalization of the proteins studied. With this, we demonstrated that although PAX5 expression occurred, it was not sufficient to inhibit NOTCH1 expression and that the translation of the protein is inhibited by different mechanisms, such as aberrant activation of the NOTCH pathway, which is a regulator of the activation of the NF-kB signaling pathway and has anti-apoptotic activity in RS cells [ 28 ]. Additionally, at the same time, it activates the NOTCH1 receptor, which inhibits the expression of B genes.…”

Section: Discussionmentioning

confidence: 99%

Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein–Barr in Pediatric Patients

et al. 2020

View full text Add to dashboard Cite

NOTCH1 and PAX5 participate in the proliferation and differentiation of B and T lymphocytes. Their expression can be modified by activation of NOTCH1, induced by the Epstein–Barr (EBV) viral proteins identified as LMP1 and LMP2. To identify whether PAX5, NOTCH1, and EBV latency genes participate in the oncogenic process of pediatric patients with classical Hodgkin lymphoma (cHL), the present study aimed to identify the variable expression of NOTCH1 among disease subtypes and to assess its effect on PAX5 expression. A total of 41 paraffin-embedded tissues from Mexican pediatric patients with cHL were analyzed. The expression of CD30, CD20, NOTCH1, PAX5, and LMP1 was evaluated by immunohistochemistry and immunofluorescence. EBV detection was performed by in situ hybridization. Out of all cases, 78% (32/41) of the cHL cases were EBV positive. NOTCH1 expression was detected in 78.1% (25/32) of EBV-positive cases, nodular sclerosis being the most frequent subtype (11/25, 44%). In cases where the expression of both genes was identified, double immunofluorescence assays were conducted, finding no colocalization. We found that Reed–Sternberg cells had aberrant expression compared to their cells of origin (B lymphocytes) due to the molecular mechanisms involved in the loss of expression of PAX5 and that the identification of NOTCH1 could be considered as a candidate diagnostic/prognostic marker and a therapeutic target in pediatric cHL.

show abstract

CD15, CD30, and PAX5 evaluation in Hodgkin's lymphoma on fine‐needle aspiration cytology samples

Cited by 22 publications

References 37 publications

CD15 and CD15s in The Anticancer Therapy

CD15 and CD15s in The Anticancer Therapy

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review

Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein–Barr in Pediatric Patients

Contact Info

Product

Resources

About